Labcorp Holdings Inc. (LH)
Health Care · Health Care Services · US stock · S&P 500 component
$317.95
▼ -7.12 (2.19%)
Fair valueFair
$303 −4.8% to fair value
$151fair band $212–$393$454
Day's range
$316.12 – $327.50
52-week range
$242.07 – $341.06
About Labcorp Holdings Inc.
Labcorp provides clinical laboratory testing and drug development services. Doctors, hospitals, health systems, employers and individual patients use its diagnostic testing network, which covers routine blood work as well as specialised genetic and cancer tests, while pharmaceutical and biotechnology companies use its laboratory and clinical trial services to bring new medicines to patients. The company is organised into a diagnostics business and a biopharma services business.
Labcorp earns revenue from fees for patient tests, paid by insurers, government programmes, employers and patients, and from research services. Sales for the last twelve months came to $14.3 billion, up 5.6% a year across the last three years. The operating margin is 10.4%, and the business earns a profit of 8% on the capital invested in it. It has net debt of 2.6 times EBITDA. The company pays a dividend with a yield of 0.9%. On the site's X-Ray Score it receives 46 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $242.07 – $341.06Volume 706,000Daily, split-adjusted
Vitals
Market cap$26.1B
52-week range$242.07 – $341.06
Volume (last day)706,000
P/E (TTM)26.3
EBIT / EV yield4.7%
Free-cash-flow yield4.4%
Dividend yield0.9%
Revenue (TTM)$14.3B
Net income (TTM)$1.0B
Operating margin10.4%
Return on capital8.3%
Debt incl. leases$5.9B
Cash & securities$142M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$303model spread $290 – $314
Fair
−4.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $318
Undervalued < $212Fair $212 – $393Overvalued > $393
10-year DCF (market-scaled)
$197
Peer multiples
$331
Earnings power floor (not blended)
$135
Fundamentals-adjusted multiple
$379
Growth the price implies
13.9%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
52/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield4.7%
Free-cash-flow yield4.4%
Fair value vs price1.0×
Growth
Weak
42/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)5.6%
EPS growth (3y)-9.2%
Growth consistency100%
Profitability
Weak
32/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital8.3%
Operating margin10.4%
Gross profitability22.4%
Financial health
Fair
57/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.6×
Interest cover6.6×
Dividends
Fair
50/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.9%
Dividends vs free cash flow20%
Dividend growth7.2%
Quarterly results: last 6 quarters
+5.3%
Mar '25
+9.5%
Jun '25
+8.6%
Sep '25
+5.6%
Dec '25
+5.8%
Mar '26
+5.8%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $3.7B, diluted EPS $3.64.
Compare with peers
DVA Davita Inc.66 CI Cigna Group66 DGX Quest Diagnostics Inc57 CVS CVS HEALTH Corp52Other Health Care Services companies by X-Ray Score.
Fundamentals checklist
● 2 Good · ● 10 Average · ● 4 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldAverage
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioAverage
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 43/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $13.1B | $11.9B | $12.2B | $13.0B | $14.0B |
| Operating income | $3.0B | $1.4B | $726M | $1.1B | $1.4B |
| Net income | $2.4B | $1.3B | $418M | $746M | $877M |
| Operating cash flow | $3.1B | $2.0B | $1.3B | $1.6B | $1.6B |
| Operating margin | 23.2% | 12.1% | 6.0% | 8.4% | 9.9% |
| Free cash flow | $2.7B | $1.5B | $874M | $1.1B | $1.2B |
| Diluted EPS | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
11 bullish · 3 neutral · 2 bearish
Weekly
Strongly bullish
10 bullish · 1 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 314.8 | Bullish |
| EMA 10 | 315.9 | Bullish |
| SMA 20 | 312.1 | Bullish |
| EMA 20 | 315.1 | Bullish |
| SMA 50 | 320.2 | Bearish |
| EMA 50 | 312.7 | Bullish |
| SMA 100 | 299.0 | Bullish |
| EMA 100 | 302.7 | Bullish |
| SMA 200 | 282.4 | Bullish |
| EMA 200 | 288.7 | Bullish |
Oscillators (daily)
| RSI (14) | 53.12 | Neutral |
| MACD (12, 26) | 0.32 | Bullish |
| Momentum (12) | 3.19 | Bullish |
| Stochastic %K (14) | 61.48 | Neutral |
| Williams %R (14) | -38.52 | Neutral |
| CCI (20) | 133.5 | Bearish |
Pivot points (classic, last session)
S3 302.2 | S2 309.1 | S1 313.5 | Pivot 320.5 | R1 324.9 | R2 331.9 | R3 336.3 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.88 USD
Yield on today's price
0.91%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 28 Aug 2026 | 0.7200 |
| 29 May 2026 | 0.7200 |
| 27 Feb 2026 | 0.7200 |
| 26 Nov 2025 | 0.7200 |
| 28 Aug 2025 | 0.7200 |
| 29 May 2025 | 0.7200 |
| 27 Feb 2025 | 0.7200 |
| 26 Nov 2024 | 0.7200 |
| 29 Aug 2024 | 0.7200 |
| 28 May 2024 | 0.7200 |
| 26 Feb 2024 | 0.7200 |
| 7 Nov 2023 | 0.7200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
LH SEC filings
30 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
22 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
10 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
28 Aug 2026
8-KSEC EDGAR
Regulation FD disclosure
17 Aug 2026
8-KSEC EDGAR
Regulation FD disclosure
14 Aug 2026
8-KSEC EDGAR
Director or officer change
5 Aug 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.